中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
4期
418-421
,共4页
糖尿病,2型%胰升糖素样肽1%随机对照试验%系统评价
糖尿病,2型%胰升糖素樣肽1%隨機對照試驗%繫統評價
당뇨병,2형%이승당소양태1%수궤대조시험%계통평개
Diabetes mellitus,type 2%Glucagon-like peptide-1 analogue%Randomized controlled trails%Systematic review
目的 系统评价胰升糖素样1肽(GLP-1)类似物治疗2型糖尿病的有效性和安全性.方法 计算机检索Pubmed、Ovid、SpringerLink、Cochrane图书馆、中国生物医学文献数据库(CBM)及万方数据库.检索时间由建库截至2010年9月.按Cochrane系统评价的方法 评价研究的质量,应用RevMan4.2软件进行Meta分析;不能合并的数据,进行描述性分析.结果 本研究共纳入23个随机对照试验进行分析.Meta分析结果 显示在降低糖化血红蛋白[加权均数差(WMD)=-0.89,95%可信区间(CI)-1.02～-0.77,P＜0.01]和降低体重方面(WMD=-1.16,95% CI-1.75～-0.56,P＜0.01),GLP-1类似物组均优于安慰剂组或其他降糖药组.GLP-1类似物组的低血糖事件发生率高于安慰剂组(RR=1.81,95%CI 1.32～2.49,P＜0.01),但与其他降糖药组相当(RR=0.59,95%CI 0.34,1.01,P=0.06).GLP-1类似物组的胃肠道的不良反应率高于安慰剂组(RR=3.30,95%CI2.43～4.49,P＜0.01).结论 现有的临床证据显示,GLP-1类似物治疗2型糖尿病疗效较好,且相对安全,主要的不良反应为胃肠道不良反应.
目的 繫統評價胰升糖素樣1肽(GLP-1)類似物治療2型糖尿病的有效性和安全性.方法 計算機檢索Pubmed、Ovid、SpringerLink、Cochrane圖書館、中國生物醫學文獻數據庫(CBM)及萬方數據庫.檢索時間由建庫截至2010年9月.按Cochrane繫統評價的方法 評價研究的質量,應用RevMan4.2軟件進行Meta分析;不能閤併的數據,進行描述性分析.結果 本研究共納入23箇隨機對照試驗進行分析.Meta分析結果 顯示在降低糖化血紅蛋白[加權均數差(WMD)=-0.89,95%可信區間(CI)-1.02～-0.77,P＜0.01]和降低體重方麵(WMD=-1.16,95% CI-1.75～-0.56,P＜0.01),GLP-1類似物組均優于安慰劑組或其他降糖藥組.GLP-1類似物組的低血糖事件髮生率高于安慰劑組(RR=1.81,95%CI 1.32～2.49,P＜0.01),但與其他降糖藥組相噹(RR=0.59,95%CI 0.34,1.01,P=0.06).GLP-1類似物組的胃腸道的不良反應率高于安慰劑組(RR=3.30,95%CI2.43～4.49,P＜0.01).結論 現有的臨床證據顯示,GLP-1類似物治療2型糖尿病療效較好,且相對安全,主要的不良反應為胃腸道不良反應.
목적 계통평개이승당소양1태(GLP-1)유사물치료2형당뇨병적유효성화안전성.방법 계산궤검색Pubmed、Ovid、SpringerLink、Cochrane도서관、중국생물의학문헌수거고(CBM)급만방수거고.검색시간유건고절지2010년9월.안Cochrane계통평개적방법 평개연구적질량,응용RevMan4.2연건진행Meta분석;불능합병적수거,진행묘술성분석.결과 본연구공납입23개수궤대조시험진행분석.Meta분석결과 현시재강저당화혈홍단백[가권균수차(WMD)=-0.89,95%가신구간(CI)-1.02～-0.77,P＜0.01]화강저체중방면(WMD=-1.16,95% CI-1.75～-0.56,P＜0.01),GLP-1유사물조균우우안위제조혹기타강당약조.GLP-1유사물조적저혈당사건발생솔고우안위제조(RR=1.81,95%CI 1.32～2.49,P＜0.01),단여기타강당약조상당(RR=0.59,95%CI 0.34,1.01,P=0.06).GLP-1유사물조적위장도적불량반응솔고우안위제조(RR=3.30,95%CI2.43～4.49,P＜0.01).결론 현유적림상증거현시,GLP-1유사물치료2형당뇨병료효교호,차상대안전,주요적불량반응위위장도불량반응.
Objective To systematically review the efficacy and safety of glucagon-like peptide (GLP)-1analogue in the treatment of type 2 diabetes. Methods Literature search was conducted through Pubmed, Ovid, SpringerLink, Cochrane, CBM and Wanfang data by the end of September 2010. The selection of studies, assessment of methodological quality and data extraction were performed according to Cochrane Handbook for systematic reviews and predefined criteria. Meta analysis was carried out by the use of software RevMan4.2 and descriptive qualitative analysis was done when necessary. Results Twenty-three clinical trials met the inclusion criteria. The results of Meta-analysis indicated that GLP-1 analogue group showed better clinical outcomes than placebo group and other antidiabetic drug group, regarding the reduction of HbA1c and loss of body weight. Compared with placebo group, GLP-1 analogue group had higher hypoglycaemia rate, which was similar to the rate in other antidiabetic drug group. GLP-1 analogue group had high risk of gastrointestinal side effects. Conclusions The evidence currently available suggests that GLP-1 analogue has good efficacy and tolerability. The common adverse effects are gastrointestinal side effects.
